



UNIVERSITY OF LEEDS

This is a repository copy of *Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/160719/>

Version: Accepted Version

---

**Article:**

Manzano, A [orcid.org/0000-0001-6277-3752](https://orcid.org/0000-0001-6277-3752), Eskyte, I [orcid.org/0000-0001-9486-0033](https://orcid.org/0000-0001-9486-0033), Ford, HL et al. (8 more authors) (2020) Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis. *Patient Education and Counseling*, 103 (12). pp. 2540-2547. ISSN 0738-3991

<https://doi.org/10.1016/j.pec.2020.05.014>

---

© 2020 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Table 4: Main factors preventing pwRRMs reporting new symptoms to MS team during the wait and see phase**

<b>MAIN FACTORS</b>	
1.	Relapses are heterogeneous and there are knowledge gaps and there can be disagreement between pwRRMs and neurologists on what RRMS activity looks like.
2.	Newly diagnosed pwRRMs receive little information and had limited experiential knowledge about RRMS.
3.	There are scarce planned follow-up visits in clinical pathways for those who are not taking DMTs who can often have long-periods of time without contacting specialist MS staff.
4.	The presence of emotional barriers (guilt, regret, denial, failure) which are related to accepting that their “non-RRMS” has advanced to “RRMS” and that their non-biomedical strategies had failed to protect them from transitioning to the next RRMS stage.